Venus Medtech (Hangzhou) Inc is a healthcare company based in China, specializing in developing and commercializing transcatheter solutions for structural heart diseases. With a focus on sustainability and governance, the company offers two TAVR products - VenusA-Valve and VenusA-Plus, to treat severe Aortic Stenosis (AS) using a transcatheter approach. Despite its high risk ESG score of 33.8, Venus Medtech continues to see majority of its revenue coming from Mainland China.